• Regenacy Pharmaceuticals Announces Patent Issuance for Ricolinostat americanpharmaceuticalreview
    August 20, 2018
    Regenacy Pharmaceuticals announced the issuance of U.S. Patent No. 10,040,769 covering the use of ricolinostat (ACY-1215) for the treatment of diabetic peripheral neuropathy (DPN). Ricolinostat is an oral, selective inhibitor of the microtubule modifying
PharmaSources Customer Service